Lexaria Average Receivables from 2010 to 2024

LEXXW Stock  USD 0.78  0.03  4.00%   
Lexaria Bioscience Average Receivables yearly trend continues to be fairly stable with very little volatility. Average Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, Lexaria Bioscience Average Receivables regression line of quarterly data had mean square error of 5.4 B and geometric mean of  137,254. View All Fundamentals
 
Average Receivables  
First Reported
2010-12-31
Previous Quarter
185.1 K
Current Value
194.3 K
Quarterly Volatility
99.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 125.2 K or Other Operating Expenses of 3.2 M, as well as many indicators such as Price To Sales Ratio of 105, Dividend Yield of 0.0 or PTB Ratio of 54.87. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Average Receivables Growth Pattern

Below is the plot of the Average Receivables of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Average Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
Average Receivables10 Years Trend
Slightly volatile
   Average Receivables   
       Timeline  

Lexaria Average Receivables Regression Statistics

Arithmetic Mean170,547
Geometric Mean137,254
Coefficient Of Variation58.08
Mean Deviation88,740
Median188,514
Standard Deviation99,051
Sample Variance9.8B
Range216.8K
R-Value0.70
Mean Square Error5.4B
R-Squared0.48
Significance0
Slope15,419
Total Sum of Squares137.4B

Lexaria Average Receivables History

2024194.3 K
2023185.1 K
2022188.5 K
2016272.1 K
201581.2 K

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Average Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Average Receivables185.1 K194.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.